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A B S T R A C T
Purpose: Hypothalamic hamartoma (HH) is the main structural cause of central precocious puberty
(CPP). HH is frequently associated with cognitive impairment and epileptic encephalopathies. Disease
severity in case series from neurology services may be biased towards more neurologically impaired
patients.
Aim: To perform a prospective cognitive evaluation in patients with HH presenting with CPP in an
endocrinology outpatient clinic setting.
Methods: We evaluated ﬁfteen consecutive patients with CPP due to HH presenting to an endocrinology
outpatient clinic. CPP was diagnosed at a median age of 0.7 yr (0.4–7 yr). Mean age at neurologic
evaluation was 13.9 yrs. Eight patients (53.3%) were male. Epileptic seizures occurred in 5/15 (33%)
patients. Two patients presented a single unprovoked seizure (SUS). Three patients were diagnosed with
epilepsy. Cognitive evaluation, using age-appropriate Wechsler Intelligence Scale, was performed in 11
patients.
Results: All patients without epilepsy, including two patients with a history of a SUS, had normal
neurologic and cognitive evaluation. Epilepsy and SUS were only seen in patients with sessile HH. Three
patients with epilepsy presented cognitive or behavioral ﬁndings. Reduced intelligence quotients (IQ), in
the borderline range, were noted in both patients with epilepsy who underwent full cognitive
evaluation. We found no signiﬁcant correlation between HH diameter or shape and mean full-scale IQ.
Conclusions: Patients who presented with isolated CPP without epilepsy displayed normal cognition
when evaluated after a mean period of 13 years. Occurrence of epilepsy, seen in a minority of patients,
but not of a single seizure, was associated with mild cognitive deﬁcit and behavioral disturbances in this
case series.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Hypothalamic hamartomas (HH) are congenital, non-neoplastic
tumor-like masses containing normal-appearing mature cells.1,2 HH
presentation may include endocrine (central precocious puberty –
CPP) or neurological abnormalities (epilepsy and cognitive im-
pairment).3,4 Asymptomatic cases have also been reported.3,4* Corresponding author at: Hospital das Clı´nicas, Faculdade de Medicina da
Universidade de Sa˜o Paulo, Disciplina de Endocrinologia e Metabologia, Av. Dr.
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http://dx.doi.org/10.1016/j.seizure.2012.09.013HH are composed of ectopic GnRH neurons or TGFa-producing
astroglial cells that lead to premature activation of pulsatile GnRH
release and consequent CPP.5 HH represents the main organic
cause of CPP, usually manifesting before age four.1–4
Neurological symptoms associated with HH characteristically
include gelastic (brief spells of laughter) or dacrystic (crying)
seizures, usually presenting in infancy,1–4,6 with later occurrence
of different seizures types, including focal and generalized
seizures, that may be associated with an epileptic encephalopathy.
Developmental delay, loss of acquired developmental milestones
and behavioral disturbances frequently accompany this scenario,
and are considered a hallmark of HH.1,7,8 Case series in which
neurologic features are described may be biased towards more
severe neurologic involvement. To our knowledge, no study hasvier Ltd. All rights reserved.
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CPP outside a neurology clinic setting.
We evaluated cognitive functioning in a series of patients who
had presented with CPP due to HH to an Endocrine outpatient
tertiary referral center.
2. Patients and methods
Fifteen consecutive patients (8/15 or 53.3% boys) with CPP due
to HH were identiﬁed in the Developmental Endocrinology Unit
Outpatient Clinic at Hospital das Clinicas da Faculdade de Medicina
da Universidade de Sao Paulo, Brazil.
Written informed consent was obtained from patients, parents
or legal guardians, according to procedures approved by the
institutional research ethics committee.
Precocious puberty was diagnosed when secondary sexual
features appeared before age eight in girls and age nine in boys, and
was classiﬁed according to Marshall and Tanner criteria.9,10
Hormone pubertal levels were deﬁned as: basal LH greater than
0.6 U/L and/or GnRH-stimulated LH peak greater than 15 U/L for
girls and 25 U/L for boys (by radioimmunoassay) or greater than
6.9 U/L for girls and >9.6 U/L for boys (by immunoﬂuorometric
assay).11 Bone age was assessed with the Greulich and Pyle
method.12
All patients underwent at least one brain magnetic resonance
imaging (MRI) study, that included pre- and post-gadolinium
enhanced sagittal T1-weighted images, as well as coronal T1- and
T2-weighted images, with 3-mm slices.13 HH was diagnosed by the
ﬁnding of a noncontrast-enhancing mass in the tuber cinereum
region, isointense on T1-weighted images and iso- or slightly
hyperintense on T2 weighted images (see Fig. 1).
2.1. Neurological evaluation
Patients underwent a complete neurologic evaluation, probing
for early motor and cognitive milestones, current cognitive status,
and occurrence of isolated or recurrent epileptic seizures (L.H.M.C.,
L.K.F., L.R.T.). Seizures were classiﬁed as gelastic or dacrystic, focal
onset or primary generalized seizures (tonic-clonic, tonic or
atonic). A sleep and awake digital EEG after sleep deprivation
with standard activation procedures (photic stimulation and
hyperventilation) was obtained in all but one patient. RepeatFig. 1. Magnetic resonance with coronal and sagittal T1-weighted images of four childre
ectopic mass, isointense to gray matter, located in the tuber cinereum. Arrows indicat
abutting the right mammillary body, sparingthe left side. C – central lesion located betwe
bodies’ level. RM images display the relationship between hamartoma and third ventricle
epileptic seizures.MRI studies were obtained to characterize hamartoma’s morpho-
logical features (diameter and shape). A neuroradiologist (C.C.L.)
classiﬁed hamartoma shape as: pedunculated (attached to the
tuber cinereum without hypothalamus displacement) or sessile
(broad-based hypothalamus attachment).14
2.2. Cognitive evaluation
Two neuropsychologists (C.C.A., N.B.) from the Neurology
Division performed cognitive assessment in two 1-h sessions.
Age appropriate Brazilian–Portuguese validated versions of the
Wechsler Intelligence Scales were administered, yielding Verbal
(VIQ), performance (PIQ), and full-scale intelligence quotients
(FSIQ). Wechsler Intelligence Scale for adults (WAIS-III)16 was used
for one patient older than 17 years, Weschler Preschool and
Primary Scale of Intelligence-Revised (WPPSI-R)17 was used for
one child under age six years, and the remaining patients, aged 6–
16 years, were evaluated with Wechsler Intelligence Scale for
children (WISC-III).15 FSIQ was classiﬁed as borderline, low
average, average, high average, high and very high. IQ scores were
compared between patients with and without epilepsy, and for
patients with isolated unprovoked seizures.
2.3. Statistical analysis
Data were analyzed with SigmaStat for Windows Version 3.5
(Systat, Inc., 2006), and are presented as median and range for
variables with non-Gaussian distribution or mean and standard
deviation for normal distribution variables (Kolmogorov–Smirnov
test). Median HH diameters were compared with Mann–Whitney
test. Pearson’s correlation was calculated for HH diameter and IQ.
Categorical data were compared with Fisher’s exact test and
logistic regression analysis. Comparisons of VIQ, PIQ and FSIQ
means among CPP patients without epilepsy, with SUS and
epilepsy were performed with one-way analysis of variance
(ANOVA). Statistical signiﬁcance was considered at p < 0.05.
3. Results
Median chronological age (CA) of secondary sexual features
presentation in girls was 0.5 yr (0.4–7 yr) and 2.0 yr (0.5–5 yr) in
boys. Median CA on initial endocrine evaluation was 2.3 yr (0.9–8.1n with CPP due to HH. Lesions are characterized by a solid non-constrast enhacing
e HHs. A – large mass involving mammillary bodies and infundibulum B – lesion
en the infundibulum and mammillary bodies. D – lesion located at the mammillary
, infundibulum, and mammillary bodies (Boyko criteria).14 Patients B and C present
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and Tanner criteria,9 breast development stage in girls ranged from
2 to 5, with pubic hair ranging from 1 to 5. All boys presented testis
size stage ranging from 2 to 4 and pubic hair development from 1
to 4.10 Mean bone age (BA) was 5.6  3.9 yr (1–11 yr) in girls and
5.2  5 yr (0.75–14 yr) in boys, according to Greulich and Pyle.12
Mean BA advancement in relation to CA was 2.3 yr in girls and 1.9 yr in
boys. All patients had GnRH-stimulated LH levels in pubertal range
and underwent treatment with long-acting GnRH analogs (leuprolide
acetate 3.75 mg every 28 days) with adequate pubertal suppression.
3.1. Neurological evaluation
All patients underwent neurologic evaluation. Median age at
evaluation was 13.9 yr (4–24 yr). Prenatal, birth and perinatal
history was unremarkable in all patients, as was early develop-
mental milestones achievement.
Ten of the 15 (66%) patients were considered normal from a
neurological and cognitive standpoint (Table 1). These ten patients
had adequate school performance, as measured by appropriate
grade for age and academic achievement (no failed grades). One
patient in this group had a college degree. None of these patients
reported behavioral or psychiatric problems. There was no history
of isolated seizures or epilepsy in this group. Nine of ten patients
underwent an EEG study, which were read as normal.
Five patients presented abnormal ﬁndings on neurological
evaluation (Table 2). Two reported a single event suggestive of an
unprovoked epileptic seizure.
One patient (patient 11) had a history of an isolated brief
afebrile episode of unresponsiveness and staring, without associ-
ated motor phenomenae that lasted approximately 1 min, at age
20 months, sugestive of a focal seizure with impairment of
consciouness. The patient is currently 17 years old and has no
academic or social difﬁculties. EEG was normal.
Another patient (patient 12), currently six years old, presented
an isolated afebrile episode at age nine months, described as a
generalized tonic clonic seizure preceded by left leg jerking,
suggestive of a focal motor seizure. This event occurred shortly
after vaccination and did not recur. The patient has no current
neurologic or behavioral difﬁculties. EEG was normal.
Three patients had epilepsy. One patient (patient 13), currently
aged 19, reported typical gelastic seizures since age eight months.
These seizures do not impair consciousness, last 15–40 s, and are
preceded by peculiar feeling in his head and upper abdomen. The
patient reported two previous episodes of generalized tonic-clonic
seizures that occurred during sleep, around age 12. Generalized
seizures did not recur after introduction of antiseizure medication.
Gelastic seizures still occur daily, several times a day, despiteTable 1
Neurological and cognitive features of patients with CPP due to HH without seizures.
Patient Gender CA at NC interview (yr) MRI 
HH size (mm) 
1 F 17 8 
2 F 15 7 
3 F 13 4 
4 F 6 11 
5 F 4 10 
6 F 24 13 
7 M 14 11 
8 M 14 6 
9 M 17 10 
10 M 14 30 
F: female; M: male; P: pedunculated; S: sessile; NA: not available; CA: chronological age;
high (121–127); high average (111–120); average (91–110); low average (81–90); bor
a WAIS-III.
b WPPSI-R, remaining patients underwent WISC-III.treatment with a two antiepileptic drug regimen (carbamazepine
and clonazepam). The patient completed the eighth grade, but does
not currently attend school or work. He suffers from severe social
isolation and rarely leaves his home. EEG shows epileptiform
activity in the posterior left cerebral quadrant.
The second patient (patient 14), currently 14 yr, had three
generalized tonic–clonic seizures preceded by a vague nonspeciﬁc
feeling. The patient denied other seizure types, including gelastic
seizures. The patient was not on antiepileptic drugs until
neurological evaluation, when carbamazepine was introduced.
EEG, obtained prior to treatment, was normal. This patient also
reported school difﬁculties. He currently attends the sixth grade,
after having failed two grades.
The third patient (patient 15), now 15 yr, had gelastic seizures
since age three months and generalized tonic–clonic seizures since
age three. EEG shows focal epileptiform activity in the left frontal-
central region.
3.2. Cognitive evaluation
Eleven out of the 15 patients underwent cognitive evaluation.
Seven patients without seizures (Table 1) had IQ scores ranging
from low average to high. The two patients with an isolated
epileptic seizure showed average high and very high IQ scores
(Table 2). Two of the three patients with epilepsy (Table 2)
underwent a complete cognitive evaluation. Patient 13 was unable
to complete cognitive evaluation due to social phobia. The two
patients with epilepsy had borderline IQ scores.
Mean FSIQ score of CPP patients without epilepsy was
106.1  14.1, 121.5  12 for those with SUS, and 78.5  4.9 for those
with epilepsy (p = 0.029, ANOVA). Mean PIQ score of CPP patients
without epilepsy was 107.7  16.6, 120.5  12 for those with SUS, and
82  11.3 for those with epilepsy (p = 0.09, ANOVA). Mean VIQ score of
CPP patients without epilepsy was 104.4  14.1, 119.5  9.2 for those
with SUS, and 79.5  2.1 for those with epilepsy (p = 0.037, ANOVA).
3.3. Neuroimaging studies
In patients without epilepsy, HH had a median diameter of
10 mm (4–30 mm). Regarding shape, ﬁve of ten were classiﬁed as
pedunculated; the other ﬁve had sessile masses (Table 1).
HH of the three patients with epilepsy had a median diameter of
13 mm (10–20 mm). All HH in this group were sessile (Table 2).
Median HH diameter did not differ between CPP patients with and
without epilepsy (p = 0.39). Although all CPP patients with
neurological manifestation had sessile HH, there was no inﬂuence
of HH shape on epilepsy occurrence (p = 0.1). Patients that
presented SUS also had sessile HH.Interictal EEG IQ score
HH shape
P Normal 106 Averagea
P Normal 108 Average
P Normal 118 High average
S Normal NA NA
S Normal 106 Averageb
S Normal NA NA
P Normal 127 High
P Normal 93 Low average
S NA NA NA
S Normal 85 Low average
 IQ: intelligence quotient; HH: hypothalamic hamartoma IQ Scale: very high (>127);
derline (66–80).
Table 2
Neurological and cognitive features of patients with CPP due to HH with seizures.
Patient Gender CA at NC interview (yr) MRI Epilepsy Seizure features Interictal EEG IQ Score
HH size (mm) HH shape
11 M 17 19 S No Isolated (20 mo) Normal 130 Very high
12 M 6 5 S No Isolated (9 mo) Normal 113 High average





14 M 14 10 S Yes CPS ! TS(10 years) Normal 75 Borderline
15 F 15 13 S Yes Gel ! CPS ! GTC Left frontal-central
epileptiform discharges
82 Borderline
F: female; M: male; P: pedunculated; S: sessile; CPP: central precocious puberty; NA: not available; CA:chronological age; NC: neurocognitive; Gel: Gelastic; CPS: complex
partial seizure; GTC: generalized tonic–clonic seizure. IQ Scale: borderline (66–80); high average (111–120); very high (>127). Patients underwent WISC-III.
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FSIQ (r = 0.07, p = 0.8), as well as no signiﬁcant differences in
mean IQ between CPP patients with pedunculated and sessile HH
(p > 0.05).
4. Discussion
Classical neurologic manifestations of HH are medically
refractory epilepsy, formerly referred to as catastrophic epilepsy,
associated with severe cognitive impairment, mental retardation,
behavioral and psychiatric symptoms. This symptom constellation
characterizes an epileptic encephalopathy. These patients may also
present CPP. Prevalence of neurologic and endocrine abnormalities
may differ in patient populations referred to neurology or
endocrine clinics.1–3 Contrary to what is habitually observed in
the patient population referred to neurology clinics, patients
evaluated in endocrine clinics may present less severe neurologic
involvement.8We report the results of a neurological and cognitive
evaluation in a consecutive case series of 15 patients with HH
identiﬁed in a non-neurologic outpatient clinic.
Epileptic seizures frequently occur in association with HH. In
our series, epilepsy was seen in only 3/15 (20%) of CPP patients and
2/15 (13%) presented with an isolated unprovoked seizure. Lower
epilepsy prevalence in this series is explained by a selection bias
related to case ascertainment from a non-neurologic outpatient
clinic setting. In a large case series of 277 HH patients, 63% of
patients had CPP, 61% had seizures and 27% presented with both
CPP and seizures.18,19
Gelastic seizures are the hallmark of epilepsy associated with
HH and usually manifest in infancy. Invasive depth electrode
recordings documented ictal onset of gelastic seizures in the
hamartomatous lesion.18,19,22 Different seizure types may also
occur in this setting, including focal and generalized seizure. It is
unclear if these different seizure types involve propagation of
discharges from the deep-seated HH lesion or if these seizures may
have an independent cortical origin.8,22 Surgical treatment of the
hamartoma has been reported to lead to complete seizure
resolution, including of non-gelastic seizures.18–21 Epilepsy has
been associated with sessile HH.3 Some studies have suggested
that HH size may play a role in seizure origin.3 Two of the three
patients with epilepsy ﬁrst presented gelastic seizures and then
presented generalized tonic–clonic seizures. Both these cases
maintain persistent seizures despite medical treatment with anti-
seizure medication. One patient did not present gelastic seizures,
and reported occasional generalized tonic–clonic seizures. None of
the cases presented an epileptic encephalopathy, which is usually
associated with frequent, refractory, drop attacks, accompanied by
other seizure types.20,21 A bias toward less severe forms of epilepsy
in this series is again explained by case selection in a non-
neurologic patient universe.
Association of epilepsy and variable degrees of cognitive decline
is a well-recognized complication of medically refractory epilep-sy.4 The underlying neurobiological processes involved in cogni-
tive deterioration in epileptic encephalopathies, including HH-
related encephalopathies, remain incompletely under-
stood.4,20,21,23 Previous reports of HH case series have underscored
the ﬁndings of intact or mildly impaired cognition in patients with
adult-onset HH-related epilepsy and also in patients presenting
with focal epilepsy syndromes, specially temporal lobe epilep-
sy.6,21,24 These series included only patients with HH-related
epilepsy and cognitive decline was linked with epilepsy severi-
ty.6,21,24 Cognitive and neurologic evaluation in our case series
disclosed intact cognition and absence of behavioral manifesta-
tions in patients without epilepsy. Patients with an isolated
unprovoked seizure also did not display cognitive or behavioral
abnormalities. These patients, usually not represented in series
drawn from neurology or epilepsy clinics represent the benign
spectrum of HH. Patients with epilepsy from our cohort presented
less severe forms of epilepsy than habitually observed in HH from
neurology services. Remote occurrence of SUS in two patients in
this series did not inﬂuenced cognition.
The three patients with epilepsy had signiﬁcantly lower IQ
scores than their counterparts without epilepsy. Two patients
presented with less severe forms of refractory epilepsy, and one
patient presented with occasional tonic–clonic seizures, that had
not been previously treated. Two of the patients with epilepsy
displayed cognitive functioning in the borderline IQ range. One
patient displayed severe psychiatric symptoms with severe impact
in daily activities, but, in this patient, full assessment of cognitive
status was hindered by the patient’s inability to cooperate due to
severe social phobia. Our ﬁndings support the notion that HH
associated with epilepsy is associated with cognitive impairment,
albeit not severe in these cases.
Epilepsy cases in this study did not present with more severe
epilepsy or cognitive decline. We have previously reported a case
series of seven HH patients identiﬁed in the neurology service in
the same institution.21 Only one patient presented with precocious
puberty, and four presented with severe forms of epilepsy and
cognitive impairment, with IQ scores ranging from mild to
profound mental retardation.21 Those cases are not included in
this report.
We did not found a signiﬁcant correlation between HH size and
epilepsy occurrence. Mean HH size did not differ between patients
with and without neurologic and psychiatric symptoms. HH size
appears not to be a determinant factor of the occurrence of
psychiatric or neurologic involvement associated with HH. These
ﬁndings are in contrast with a previous study that demonstrated
that small and pedunculated HH are associated with CPP, while
large and sessile HH are associated with seizures.13
All our patients with epilepsy or isolated seizures presented
sessile HH, a ﬁnding that is concordant with other studies.
Cognitive impairment and psychiatric manifestations only oc-
curred in patients with sessile HH. However, sessile HH were also
seen in patients without epilepsy, cognitive or psychiatric
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not sufﬁcient to cause neurologic and psychiatric symptoms.
We conclude that HH presents as a spectrum of disorders. While
pedunculated HH appear to present with isolated endocrine
ﬁndings, presentation of patients with sessile HH are distributed
within a wide spectrum. Cases presenting with precocious puberty,
intact cognition without epilepsy represent the less severe end of
the spectrum. These cases may not come to the neurologist’s
attention. A more severe end of the spectrum is represented by
patients with severe epilepsy and cognitive impairment. These
patients may not present central precocious puberty. The
underlying conditions that determine the clinical presentation
in cases of sessile HH remain poorly understood.13,18,25,26
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